# Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B

> **NCT00128544** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 130 (—)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** telbivudine
- **DRUG:** valtorcitabine

## Key facts

- **NCT ID:** NCT00128544
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 130 (—)
- **Last updated:** 2017-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00128544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00128544, "Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00128544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*